Voyager Therapeutics says cash runway extends into Q2 2028
VYGR•Voyager Therapeutics said its cash runway extends into Q2 2028, with $132.1 million in cash, cash equivalents and marketable securities at September 30, 2026. The company said VY7523 imaging data remain on track for Q4 2026 and expects initial VY1706 acute safety data in Q1 2027.
1. Cash runway and trial updates
Voyager Therapeutics said lower year-over-year operating expenses extended its cash runway into Q2 2028. Cash, cash equivalents and marketable securities totaled $132.1 million at September 30, 2026. Imaging data from the VY7523 Alzheimer's trial remain on track for Q4 2026, and the last patient visit has been completed. Patient dosing for VY1706 is expected within months, pending enrollment, with initial acute safety data expected in Q1 2027.




